Interim results of Abiomed's PROTECT III post-approval study of its Impella 2.5 and Impella CP heart pumps in high-risk percutaneous coronary intervention patients showed positive interim results. "This novel, contemporary data from PROTECT III clearly demonstrates how the evolution and adoption of Impella best practices can lead to an improvement in safety and MACCE and it provides important information as we prepare for the upcoming PROTECT IV Randomized Controlled Trial of Impella in high-risk PCI," said William O'Neill, medical director of the Center for Structural Heart Disease at Henry Ford Hospital.
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.